Reaktion #95802

ord-aa74e398b9904c06bc3b9140ca47a282

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    SonstigeThe mixture is evaporated in vacuo
  2. 2
    Temperaturheated
  3. 3
    Temperaturunder reflux for 22 hours
  4. 4
    SonstigeAfter evaporation in vacuo
  5. 5
    workup.ADDITIONthe residue is treated with water
  6. 6
    Extraktionextracted three times with 30 ml of chloroform each time
  7. 7
    WaschenThe combined chloroform phases are washed three times with 20 ml of water each time
  8. 8
    Trocknendried over magnesium sulphate
  9. 9
    Sonstigeevaporated
  10. 10
    SonstigeAfter recrystallisation from ethyl acetate/n-hexane

Vorschrift

934 mg (3 mmol) of ethyl (S)-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate are stirred at 60° C. for 48 hours with 198 mg (3 mmol) of potassium cyanide in 30 ml of dry 2-propanol. The mixture is evaporated in vacuo. The residue is treated with 30 ml of 2-propanol and 198 mg (3 mmol) of potassium cyanide and heated to boiling under reflux for 22 hours. After evaporation in vacuo, the residue is treated with water and extracted three times with 30 ml of chloroform each time. The combined chloroform phases are washed three times with 20 ml of water each time, dried over magnesium sulphate and evaporated. After recrystallisation from ethyl acetate/n-hexane, there is obtained isopropyl (S)-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate of melting point 207°-208° C.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US04346033uspto-grants-1982_08